(Total Views: 362)
Posted On: 05/11/2017 2:22:28 PM
Post# of 72446
It was illustrative of what the terms of the highlighted deal-of-the-day, a mere PRE-clinical deal with revenues a decade away, would do for us (quite a lot for our current market cap).
As I noted the reduced risk to pharma (going into Phase 3) and the short time to royalties ( <2 years: QIDP Fast Track on B, 505b2 on P) would greatly improve the terms of the deal.
The whole point being that we don't need spectacular multibillion dollar terms in our first partnership to make massive gains in share price from here.
As I noted the reduced risk to pharma (going into Phase 3) and the short time to royalties ( <2 years: QIDP Fast Track on B, 505b2 on P) would greatly improve the terms of the deal.
The whole point being that we don't need spectacular multibillion dollar terms in our first partnership to make massive gains in share price from here.
(1)
(0)
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
